Opportunity
Simpler Grants.gov #RFA-CA-26-010
NIH Solicitation: Canine Cancer Immunotherapy Network (K9CIN) Clinical Trials Support
Buyer
National Institutes of Health
Posted
October 04, 2023
Respond By
January 25, 2027
Identifier
RFA-CA-26-010
NAICS
541715
This opportunity from the National Institutes of Health (NIH), via the National Cancer Institute (NCI), seeks to establish the Canine Cancer Immunotherapy Network (K9CIN) to advance research in canine cancer immunotherapy. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Scope of Work: - Support for five U01 cooperative agreements: - One Network Coordinating Center - Four clinical trial sites - Conduct clinical trials in pet dogs with naturally occurring cancers - Evaluate immunotherapeutic agents (novel and repurposed), alone or in combination with other treatments - Perform correlative studies and develop analytics to generate data translatable to human cancer treatment - Products/Services Requested: - Research services for clinical trials and network coordination - No specific products, part numbers, or OEMs listed - Unique Requirements: - Focus on translational research bridging canine and human cancer immunotherapy - Open to a wide range of eligible applicants, including educational, governmental, nonprofit, business, tribal, and foreign institutions - Place of Performance: - NIH federal office (contracting and oversight) - No specific period of performance or contract value provided
Description
This funding opportunity aims to support canine cancer immunotherapy clinical trials to evaluate safe and effective cancer treatments translatable to humans. The network will consist of five U01 awards, including one Network Coordinating Center and four recipients conducting canine clinical trials using immunotherapeutic agents alone or in combination with other treatments. The goal is to advance canine immunotherapeutic development and analytics, facilitating evaluation of novel and repurposed drugs, treatment combinations, and dosing in pet dogs. This opportunity consolidates prior funding mechanisms to streamline applications and support research benefiting both humans and dogs.